Implant-Associated P. Aeruginosa Bone And Joint Infections : Experience In A Regional Reference Center In France

Hospices Civils de Lyon94 enrolled

Overview

The aim of this study is to describe the bone or joint infection due to Pseudomonas aeruginosa in patients having implant.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Bone and Joint Infection

Interventions

Bone or joint infection due to Pseudomonas aeruginosaOTHER

Description of bone or joint infection on implant due to Pseudomonas aeruginosa

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients having BJI on implant caused by Pseudomonas aeruginosa Exclusion Criteria: \-

Locations (1)

Hospices Civils de Lyon

Lyon, France

Outcomes

Primary Outcomes

Description and rate of bone or joint infection on implant caused due to Pseudomonas aeruginosa

Description of the type of infection due to P. aeruginosa : patients and type of implant, profile of the bacterium, medical and chirurgical treatment, rate

Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)

Secondary Outcomes

Rate of adverse events occurring under medical treatment against Pseudomonas aeruginosa

description of adverse events occurring under medical treatment against Pseudomonas aeruginosa in BJI

Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)

Rate of Treatment Failure

Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin

Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.